date: Dec 20, 2021 6:35 AM EST . Very rare serious adverse events of myocarditis and pericarditis have been observed though cases typically occurred within a few days after vaccination, and were generally mild. [67][35], On 12 March 2021, Novavax announced their vaccine candidate was 96.4% effective in preventing the original strain of COVID-19 and 86% effective against the Alpha variant. [50], In March 2020, Novavax announced a collaboration with Emergent BioSolutions for preclinical and early-stage human research on the vaccine candidate. [62][63], In December 2020 Novavax started the PREVENT-19 (NCT04611802) phase III trial in the US and Mexico, funded by NIAID and BARDA. December 23, 2021, 9:30 AM. One is the vaccine developed by Janssen, approved in May, with doses due to be delivered by the end of this year, but the UK government is now planning to donate all 20m of them to developing countries, via the Covax initiative. Privacy Policy. Covid vaccines: How fast is worldwide progress? [29], The most common side effects include fever, headache, nausea, muscle and joint pain, tenderness and pain at the injection site, tiredness, and feeling unwell. [25][28] [46] As of 2021, antigens were made at Novavaxs factory Novavax CZ in the Czech Republic;[47] Novavax CZ was also marketing authorisation holder of its EU authorization. Novavax reported that a part II of its phase III study on the COVID-19 Omicron BA.1 vaccine candidate will evaluate the candidate vaccine compared with an Omicron BA.5 vaccine, as well as a . Copyright 2022 by WTOP. You have rejected additional cookies. Final data from its phase 3 trial is expected any day now, paving the way for the companies to seek regulatory approval. Dont include personal or financial information like your National Insurance number or credit card details. Heath said: It may well be that those people who have been hesitant about receiving other Covid vaccines may be more open to receiving a vaccine that uses this protein adjuvant technology; it may be something thats more familiar to them, and therefore will be happy to receive., Majeed is less convinced Novavax will make much difference to uptake but can see other benefits to such protein-based vaccines. The Novavax vaccine will be manufactured in two different facilities. The vaccine contains the SARS-CoV-2 spike protein and Matrix-M adjuvant. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Statements herein relating to the future of Novavax, its near term priorities including delivering an updated vaccine for the 2023 fall vaccination season, streamlining its investment and organizational structure and building value for Novavax from its technology platform and Matrix-M adjuvant, its operating plans, objectives and prospects, including Novavax's ability to continue as a going concern within one year after the issuance date of the financial statements for the year ended December 31, 2022, its anticipated strategic plan, its future financial or business performance, conditions or strategies, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, and a bivalent or monovalent Omicron-based / original strain based vaccine, the CIC investigational vaccine candidate, a quadrivalent influenza investigational vaccine candidate, the scope, timing and outcome of future and pending regulatory filings and actions and additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents and as a booster, are forward-looking statements. . ET. Date published: 2023-01-12. Novavax shares jump ahead of expected approval from the EU's drug regulator for its Covid-19 vaccine, which uses a more conventional technology than mRNA. If approved, the Novavax vaccine is expected to be available among the second wave of jabs to provide a . "I think some people are reassured by the decades of safety profiles which are based on this technology.". They give you the best protection against COVID-19. Effective date. Jobs could come alongside the new jab, too: in March, Boris Johnson announced that 60m doses would be made in north-east England. 20 February 2023 Before any COVID-19 vaccine is approved for use in Australia, it will be subject to the well-established and rigorous assessment and approval processes of the Therapeutic Goods Administration (TGA), part of the Department of Health. Trials were conducted before the emergence of the SARS-CoV-2 Omicron variant, which has sharply reduced the effectiveness of authorized vaccines in preventing infections. Medicine regulators also continue to collect data, so vaccine safety can be monitored and any possible adverse reactions can be investigated. The Food and Drug Administration on Wednesday authorized Novavax's protein-based Covid vaccine for adults, providing Americans with an . The agency granted EUA to. [94][95] On 19 August 2022, the FDA granted Emergency Use Authorization for the Novavax COVID19 vaccine in people aged 12-17 years. Dr. Nita Patel, Director of Antibody discovery and Vaccine development, lifts a vial with a potential coronavirus, COVID-19, vaccine at Novavax labs in Gaithersburg, Maryland on March 20, 2020 . Novavax is approved and available for use as a booster in people aged 18 years and over. The background documents are also availablehere. Australia's first human trials of a candidate COVID-19 vaccine was Novavax's NVX-CoV2373 which began in Melbourne by 26 May 2020. Six per cent also said it was because the specific vaccine they wanted was not yet available in the UK. Last month she travelled from the UK to a vaccine clinic in France to have the Novavax jab. [28] Overall efficacy against different SARS-CoV-2s was 90.4% and efficacy against moderate-to-severe disease was 100%. [24] Full results from Nuvaxovid's pivotal phase III trial were published in December 2021. Up until now, the FDA has only given the OK to three . Given these uncertainties, substantial doubt exists regarding our ability to continue as a going concern through one year from the date that these financial statements are issued. When autocomplete results are available use up and down arrows to review and enter to select. had previously been approved in Canada for another use. 2023 BBC. Novavax has further delayed the submission of data for its Covid-19 vaccine to the US regulator as the biotechnology company continues to struggle with collating consistent manufacturing . Individuals with a history of anaphylaxis to any component of the vaccine should not take it. Type: protein-based vaccine Status: Approved by Health Canada Approved for: Primary series in individuals age 12 years and older, or as a booster dose in individuals age 18 years and older How it's given: Injection in muscle (usually the upper arm) Initial results are expected mid-year 2023. Kenneth, from Bristol, says he has a health condition which makes him cautious about anything that interacts with his immune system; he has been waiting for an alternative to the two main mRNA vaccines. The government has ordered 60m doses of Novavax ahead of its expected approval. [26] Efficacy is closely related to effectiveness, which is generally expected to slowly decrease over time. The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes. Wed like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. The goal suggests the U.S. could join the U.K. on the list of countries to authorize the vaccine in the . This is when the marketing authorisation application made by the company references the decision made by the EMAs Committee for Medicinal Products for Human Use (CHMP). Novavax will host its quarterly conference call today at 4:30 p.m. WHO does not recommend pregnancy testing prior to vaccination. It is impossible to compare vaccine head-to-head due to the different approaches taken in designing the respective studies, but overall, all of the vaccines that have achieved WHO Emergency Use Listing are highly effective in preventing severe disease Whereas existing UK Covid-19 jabs instruct our cells to manufacture the coronavirus spike protein, protein-based vaccines deliver pre-made fragments of it alongside an immune-stimulating adjuvant. Well send you a link to a feedback form. Lower reactogenicity becomes particularly important in groups such as children, where the balance between vaccination and not vaccination becomes a little less clear, simply because, for example, in young children the likelihood of them having severe Covid-19 is so small, said Prof Paul Heath, the director of the Vaccine Institute at St Georges, University of London, and chief investigator of Novavaxs UK trial. News stories, speeches, letters and notices, Reports, analysis and official statistics, Data, Freedom of Information releases and corporate reports, The Medicines and Healthcare products Regulatory Agency has concluded that Nuvaxovid is safe and effective in this age group. The dial-in numbers for the conference call are (833) 974-2381 (Domestic) or (412) 317-5774 (International). These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; unanticipated challenges or delays in conducting clinical trials; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; manufacturing delays or challenges, including as a result of the timing of the anticipated regulatory requirements for the fall 2023 vaccination season; the loss of future funding from the U.S. government; the potential for an unfavorable outcome in disputes, including the pending arbitration with Gavi; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). of COVID-19 in pregnancy, the likely benefits of vaccination in the local epidemiological context, and the current limitations of safety data in pregnant persons. from 8 AM - 9 PM ET. The Interim order expired September 16, 2021 so all new . The Novavax vaccine can be offered to people who have had COVID-19 in the past. Given these uncertainties, substantial doubt exists regarding our ability to continue as a going concern through one year from the date of these financial statements are issued, it said in a statement accompanying its fourth quarter results. Britons have become so accustomed to the three Covid vaccines available in the UK that most have forgotten about two others. Persons with acute PCR-confirmed COVID-19 should not be vaccinated until after they have recovered from acute illness and the criteria for ending isolation have been met. WHO does not recommend When typing in this field, a list of search results will appear and be automatically updated as you type. In late September, Novavax entered the final stages of testing its coronavirus vaccine in the UK. [30] A post hoc analysis showed an efficacy of 86.3% against the B.1.1.7 (Alpha) variant and 96.4% against "non-B.1.1.7 strains", the majority of which were the "prototype strains" (original strain). Pfizer-BioNTech . To help pregnant women make this assessment, they should be provided with information about the risks However, there is limited evidence available on the use of Novavax (NVX-CoV2373) in a heterologous schedule. There are insufficient data still for Omicron. Get breaking news and daily headlines delivered to your email inbox by signing up here. At the time, Novavax said production should be up and running by April 2021. GAITHERSBURG, Md., Feb. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global companyadvancing protein-based vaccines with its novel Matrix-M adjuvant, today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2022. This webpage was updated on 28 September 2022 to ensure consistency of formatting. Why Alex Murdaugh was spared the death penalty, Why Trudeau is facing calls for a public inquiry, The shocking legacy of the Dutch 'Hunger Winter', Why half of India's urban women stay at home. Trial data appear to show the potential for lower reactogenicity compared with existing jabs, meaning side-effects such as injection-site swelling, fatigue, headaches and muscle pain occur less frequently. After months of promises, and a series of delays, the Novavax jab was finally approved for use in adults by the European Medicines Agency (EMA) in late December 2021, followed by the British equivalent, the MHRA, on 3 February 2022. The national drug regulator has approved the Novavax vaccine, as well as two oral treatments for vulnerable patients with COVID-19. Please visit novavax.com and LinkedIn for more information. All work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks. This article provides a summary of those interim recommendations. Novavax shares sank as much as 25% after the COVID-19 vaccine maker warned Tuesday it has "substantial doubt" about its ability to stay in business through next year and it plans cuts to its spending. Worldwide, the more vaccines the better, particularly if they are low cost and dont require freezing for storage and delivery, said Brendan Wren, professor of microbial pathogenesis at the London School of Hygiene and Tropical Medicine. Updated: Oct. 20, 2022.] A first booster dose is recommended 4-6 months after the completion of the primary series. WHO has identified pregnant persons as a high priority-use group for COVID-19 vaccination, given their increased risk of severe outcomes. The Technical Advisory Group for Emergency Use Listing listed Nuvaxovid (NVX-CoV2373) vaccine against COVID-19 and Covovax (NVX-CoV2373) vaccine against COVID-19 for emergency use on 20 December 2021 and 17 December 2021 respectively. It is expected that should Novavax be provisionally approved for use, it will require two doses. Novavax began developing its COVID vaccine in 2020 with government funding, but its vaccine did not receive final emergency-use approval until July 2022, well after mRNA vaccines from Pfizer and . FDA requires vaccination providers to report vaccine administration errors, serious adverse events, cases of multisystem inflammatory syndrome, and cases of COVID-19 that result in hospitalization or death after administration of COVID-19 vaccine under an EUA. For real-time updates including the latest press releases and news statements, see our Twitter channel at https://www.twitter.com/mhragovuk. The WHO EUL process also evaluates the quality of manufacturing along with safety and efficacy. Cookie Notice [93][20] making it the fourth COVID19 vaccine authorized in the US. Well send you a link to a feedback form. ", "By now, someone in Germany who got their first Novavax vaccine at the end of February could have had their full primary series and be getting on with their life - whereas I'm still waiting around in a sort-of personal lockdown, so that is really frustrating.". Adolescents with moderate to severe immunocompromising conditions belong to the highest priority-use group. The UK is an island in the middle that doesn't. As there is not currently sufficient evidence to date to evaluate the impact of the vaccine on transmission, public health and social measures must continue, including use of face masks, physical distancing, handwashing, appropriate ventilation, and other measures as appropriate in particular settings, depending on the COVID-19 epidemiology and potential risks of emerging variants. The independent Commission on Human Medicines and its COVID-19 Expert Working Group has carefully considered the available evidence on safety, quality and effectiveness. I want the UK to be the best place in the world to conduct clinical trials. TGA Provisional Approval of Moderna COVID-19 vaccine to include 12-17 years age group While our current cash flow forecast for the one-year going concern look forward period estimates that we have sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration. If. non-pregnant women of a similar age. On Jan. 31, Novavax formally submitted its request to the Food and Drug Administration (FDA) to have its COVID-19 vaccine approved for EUA. [32], In February 2021, the European Medicines Agency (EMA) started a rolling review of the Novavax COVID-19 vaccine (NVXCoV2373). The first part seeks to enroll a total of approximately 1,500 participants in Australia and New Zealand. Pfizer and BioNTech applied for U.S. EUA of their COVID-19 vaccine on Nov. 20, 2020. Novavax heads into 2023 with some momentum, most recently due to an agreement for the U.S. government's to buy another 1.5 million doses of its Covid-19 vaccine. Novavax is confident its Covid-19 vaccine will receive the endorsement of the Food and Drug Administration's advisory committee early this summer, executives said this week. ", Fourth Quarter 2022 and Recent Highlights, COVID-19 Vaccine Orders and Plans for the 2023 Fall Vaccination Season, COVID-19 Vaccine Clinical Development Program and Expanded Authorizations, COVID-19-Influenza Combination (CIC) Vaccine Candidate Clinical Development, Fourth Quarter and Full Year 2022 Financial Results. One hurdle to overcome is that the UK vaccine programme does not currently allow someone to choose which type of jab they are given. More than 92% of over-12s in the UK have already received at least one of those Covid jabs - but that still leaves around five million people unvaccinated. The fact that it uses a more established vaccine technology could also make it more appealing. Novavax (NVAX) shed ~26% pre-market Wednesday as B. Riley downgraded it after the COVID-19 vaccine developer warned of going concern risk with its Q4 2022 results. The Conditional Marketing Authorisation (CMA) extension granted by the MHRA is valid in Great Britain only and was approved via the European Commission (EC) Decision Reliance Route. [53], Trials have also taken place in the United Kingdom. [41][70][71], On 14 June 2021, Novavax announced overall 90.4% efficacy in the Phase III U.S. & Mexico trial that involved nearly 30,000 people aged 18 years of age and older. Dr. Stephaun Wallace receives his second injection from Dr. Tia Babu during the Novavax Covid-19 . Sponsor and vaccine. These awards were approved by the Compensation Committee of Novavax and were granted in accordance with Nasdaq Listing Rule 5635 (c) (4) and pursuant to the Novavax, Inc. 2023 Inducement Plan. TheWHO Strategic Advisory Group of Experts on Immunization (SAGE) has issuedinterim policy recommendationsfor the use of the Novavax (NVX-CoV2373) vaccine. and hospitalization due to COVID-19. The vaccine is authorized for. About 300 people at FujiFilm are said to have been working on the vaccine, though delays had prompted concerns that jobs would be hit. The most common reason for remaining unvaccinated is concern about side effects, followed by worries the jabs have not been tested sufficiently. On 19 July 2022, the US Centers for Disease Control and Prevention (CDC) recommended the Novavax COVID19 vaccine as a two-dose primary series for adults age 18 and older, thus endorsing the recommendation from the Advisory Committee on Immunization Practices (ACIP) regarding this vaccine. By Berkeley Lovelace Jr. People with an allergy to one of the components of the vaccine listed in the patient information leaflet should not receive the vaccine. Novavaxs offering is a protein-based jab similar to those used to protect against flu, and for routine childhood vaccination against pertussis (whooping cough) or meningococcal infection. Check benefits and financial support you can get, Find out about the Energy Bills Support Scheme, Medicines and Healthcare products Regulatory Agency, European Commission (EC) Decision Reliance Route, The Medicines and Healthcare products Regulatory Agency, Pfizer/BioNTech COVID-19 vaccine shelf-life extended from 5 to 31 days, says MHRA, Commission on Human Medicines advice on ibuprofen and coronavirus (COVID-19), MHRA response to JCVI advice on COVID-19 Vaccine AstraZeneca for people aged under 40, UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca, Report of the Commission on Human Medicines Expert Working Group on Optimising Data on Medicines used During Pregnancy. government. and our [58][59] A spokesperson for Novavax stated that the $1.6billion was coming from a "collaboration" between the Department of Health and Human Services and Department of Defense,[58][59] where General Gustave F. Perna has been selected as COO for Warp Speed. The Novavax jab has already been approved for use in the Philippines and Indonesia. There is no confirmed release date for the Novavax COVID-19 vaccine. Participants will be prompted to request to join the Novavax, Inc. call. Government advice on public health and social measures should continue to be followed by both vaccinated and unvaccinated individuals. [52] However, following production issues with the Johnson & Johnson and OxfordAstraZeneca vaccines at its Baltimore plant and to decrease the burden on the plant, Novavax subsequently partnered with a different manufacturer in a new agreement overseen by the U.S. The Novavax jab has already been approved for use in the Philippines and Indonesia. About the COVID-19-Influenza Combination (CIC) Vaccine Candidate Phase 2 Trial. Fujifilm last month said manufacturing was unaffected by the delay, and it planned to expand its workforce in the years to come. All rights reserved. The JCVI's chair of Covid-19, Professor Wei Shen Lim, says only that the vaccine's potential use remains "under consideration" and full advice will be published in "due course". June 14, 2021. Anyone with a body temperature over 38.5C should postpone vaccination until they no longer have a fever. We also use cookies set by other sites to help us deliver content from their services. Who can get a COVID-19 vaccine Everyone aged 5 (on or before 31 August 2022) and over can get a 1st and 2nd dose of the COVID-19 vaccine. This website is not intended for users located within the European Economic Area. In accordance with the WHO Prioritization Roadmap, the highest priority-use groups (e.g. Nuvaxovid is authorised in children aged 12-17 years in Northern Ireland under the CMA extension granted by the European Medicines Agency on 1 July 2022. The vaccine has been approved after meeting the required safety, quality and effectiveness standards. But while more than 150,000 doses have now been administered in other parts of Europe, Novavax has still not been recommended by the Joint Committee on Vaccination and Immunisation (JCVI), who advise ministers in the UK. With Novavax's unique recombinant nanoparticle technology, the non-infectious spike protein serves as the antigen that primes the immune system to recognize the virus, while Novavax's Matrix-M adjuvant enhances and broadens the immune response. Trials show the protein-based jab causes fewer side-effects and hundreds of British jobs depend on it. July 13 (Reuters) - The U.S. Food and Drug Administration authorized the use of Novavax Inc's (NVAX.O) COVID-19 vaccine on Wednesday, clearing the way for a shot whose more traditional. Most side effects - like a sore arm or headache - are mild, with the risk of a severe reaction extremely low. Of the two Phase 3 trials, both found that the efficacy of the vaccine against mild, moderate, and severe disease is 90%. Our business is subject to substantial risks and uncertainties, including those referenced above. [51] Under the partnership, Emergent BioSolutions was supposed to manufacture the vaccine at large scale at their Baltimore facility. Novavax COVID-19 Vaccine, Adjuvanted indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In Europe, the vaccine will be manufactured under the trade name Nuvaxovid and has been approved by the European Medicines Agency, and in India, the vaccine will be manufactured by In countries such as Germany, France and the Netherlands, it was quickly recommended for use - as an alternative to the mRNA vaccines, for people who may have had an allergic reaction to them in the past, or those who are still unvaccinated. We use some essential cookies to make this website work. On 13 July 2022, the FDA authorized NVX-CoV2373 for emergency use as a primary immunization (not booster) in adults. Our approval of Nuvaxovid today follows a rigorous review of the safety, quality and effectiveness of this vaccine, and expert advice from the governments independent scientific advisory body, the Commission on Human Medicines. The Novavax COVID-19 Vaccine (NVX-CoV2373) is an investigational SARS-CoV-2 vaccine for the prevention of COVID-19. He said: The AstraZeneca vaccine has similar storage requirements to Novavax but the UK government seems to have largely stopped using it.. But it is the emerging signs of reduced side-effects that could make Novavax particularly attractive. It is ending its program to buy vaccines at reduced prices from manufacturers, with purchases and costs shifting to health insurance providers. Its developer, Novavax, has pitched it as an alternative for people reluctant to take newer mRNA-based jabs. Last month, officials from the Centers for Disease Control and Prevention signed off on the use of Novavax's COVID-19 vaccine for Americans ages 18 years and older, making it the fourth COVID-19 . The Novavax's Covid-19 vaccine candidate, named Covovax, could be the first approved in the U.S. to rely on a traditional, tried-and-true inoculation method. To access the replay by telephone, dial (877) 344-7529 (Domestic) or (412) 317-0088 (International) and use passcode 1137418. I am pleased to confirm today that this authorisation has been granted, providing access to a fifth vaccine that can be used to help protect us from COVID-19. All Rights Reserved. This website is not intended for users located within the European Economic Area. Table 2 shows the dates of provisional registrations granted to COVID-19 vaccines. Novavax and the Australian government announced an advance purchase agreement for 51 million doses of Novavax's COVID-19 vaccine in January 2021. So are competitors", "COVID-19 vaccine tracker (click on 'Vaccines' tab)", "Novavax's coronavirus vaccine program is getting some help from Emergent BioSolutions", "Maryland plays an outsized role in worldwide hunt for a coronavirus vaccine", "Top Official Warned That Covid Vaccine Plant Had to Be 'Monitored Closely', "Novavax Covid vaccine shown to be nearly 90% effective in UK trial", "60m doses of new covid-19 vaccine could be made in Billingham and be ready for mid-2021", "Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine work", "Novavax starts clinical trial of its coronavirus vaccine candidate", "U.S. Will Pay $1.6 Billion to Novavax for Coronavirus Vaccine", "U.S. government awards Novavax $1.6billion for coronavirus vaccine", "Novavax Enters Final Stage of Coronavirus Vaccine Trials", "Human trials of potential coronavirus vaccine begin in Melbourne", "Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom", "A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom", "Phase 3 trial of Novavax investigational COVID-19 vaccine opens", "Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine", "Novavax says Covid vaccine is more than 89% effective", "Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine", "Novavax says its Covid-19 vaccine is 90% effective in late-stage trial", "Large study finds that vaccine maker Novavax's shot is about 90% effective", "Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trial", "EMA receives application for conditional marketing authorisation of Novavax's COVID-19 vaccine, Nuvaxovid", "EMA recommends Nuvaxovid for authorisation in the EU", "Novavax COVID-19 vaccine receives first emergency use authorization", "Philippines approves emergency use of Novavax's COVID-19 vaccine", "India Clears 2 New Vaccines And Merck's Covid Pill", "South Korea approves Novavax coronavirus vaccine", "S.Korea authorises Novavax COVID-19 vaccine, imports Pfizer pills", "TGA provisionally approves Novavax (Biocelect Pty Ltd's) COVID-19 vaccine Nuvaxovid", "TGA approves provisional determination for Biocelect Pty Ltd for COVID-19 vaccine, Nuvaxovid", "Novavax Covid jab approved by UK drugs regulator", "Health Canada authorizes Novavax's Nuvaxovid COVID-19 vaccine", "Novavax's COVID-19 shot authorized in Taiwan for adults", "Novavax Covid-19 vaccine approved for those aged 18 and above in Singapore", "Novavax's Nuvaxovid COVID-19 vaccine granted interim authorisation in Singapore", "WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries", "FDA decision on Novavax's Covid shots could be delayed to review changes in manufacturing", "FDA advisory committee recommends Novavax vaccine for use in adults", "FDA gives emergency use authorization to Novavax's Covid-19 vaccine", "CDC Recommends Novavax's COVID-19 Vaccine for Adults", "CDC endorses more traditional Novavax COVID shot for adults", "CDC Recommends Novavax COVID-19 Vaccine for Adolescents", https://en.wikipedia.org/w/index.php?title=Novavax_COVID-19_vaccine&oldid=1137662566, This page was last edited on 5 February 2023, at 20:49.